TCGA-49-4488-01A-01R-1755-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.430
- ALLOGRAFT_REJECTION+0.350
- INTERFERON_ALPHA_RESPONSE+0.330
- ADIPOGENESIS+0.300
- PEROXISOME+0.290
- FATTY_ACID_METABOLISM+0.260
- GLYCOLYSIS+0.260
- MYC_TARGETS_V1+0.260
- UV_RESPONSE_UP+0.260
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.410
- HEDGEHOG_SIGNALING-0.400
- MITOTIC_SPINDLE-0.390
- APICAL_SURFACE-0.290
- G2M_CHECKPOINT-0.290
- E2F_TARGETS-0.200
- UV_RESPONSE_DN-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.140
- KRAS_SIGNALING_DN-0.120
- MYOGENESIS-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | bc895549-854b-484f-8a6d-9e5152829bcb | — | — | 0.891 |
| 2 | SRR27320676 | — | — | 0.875 |
| 3 | TCGA-05-4418-01A-01R-1206-07 | — | cohortA4 | 0.865 |
| 4 | 57901dc3-9b2f-4271-8dd9-8fc0121d6971 | — | — | 0.858 |
| 5 | 10013d81-e167-4aa0-b548-5bb359ed403a | — | — | 0.834 |
| 6 | 2ad90ba0-8038-4bad-afa3-d176f63b42f0 | — | — | 0.834 |
| 7 | TCGA-38-4632-01A-01R-1755-07 | — | cohortA1 | 0.823 |
| 8 | TCGA-49-4494-01A-01R-1206-07 | — | cohortA1 | 0.822 |
| 9 | TCGA-BA-5152-01A-02R-1873-07 | — | — | 0.821 |
| 10 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.430 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |